Breaking News Instant updates and real-time market news.

CTMX

CytomX Therapeutics

$15.76

0.44 (2.87%)

05:09
10/15/18
10/15
05:09
10/15/18
05:09

CytomX Therapeutics initiated with a Neutral at Goldman Sachs

Goldman Sachs analyst Terence Flynn started CytomX Therapeutics with a Neutral rating and $21 price target.

CTMX CytomX Therapeutics
$15.76

0.44 (2.87%)

09/13/18
HCWC
09/13/18
INITIATION
Target $32
HCWC
Buy
CytomX Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started CytomX Therapeutics with a Buy rating and $32 price target. The analyst believes the company's Probody technology could result in the development and commercialization of optimized antibody therapeutics to address cancer, with "substantial safety and tolerability advantages to patients."
06/04/18
JEFF
06/04/18
NO CHANGE
Target $40
JEFF
Buy
CytomX early data point to some safety differentiation, says Jefferies
Jefferies analyst Biren Amin said he thinks some investors may have sought a better efficacy profile from CX-072. However, he notes that the Yervoy combo data provided at ASCO are in the dose-escalation phase and are in heavily pretreated patients, adding that safety seems improved with the CX-072 plus ipi combo. Amin has a Buy rating and $40 price target on CytomX shares, which are down $5.58, or 22%, to $19.96 in afternoon trading.
06/04/18
NOMU
06/04/18
NO CHANGE
NOMU
Buy
CytomX selloff after ASCO presentations 'unfounded,' says Nomura Instinet
After CytomX Therapeutics presented two presentations for its Probody CX-072 at ASCO, Nomura Instinet analyst Christopher Marai said the data "unequivocally demonstrated" that CX-072 is performing as expected and the selloff in the stock is "unfounded." After discussing with study investigators the real-world experience with CX-072, they noted that despite small numbers it was clear that immune-related adverse events typically associated with anti-PD-L1 agents were reduced, added Marai, who reiterates a Buy rating on CytomX shares.
06/01/18
RHCO
06/01/18
INITIATION
Target $38
RHCO
Buy
CytomX Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Peter Lawson initiated CytomX Therapeutics with a Buy rating and $38 price target. In a research note to investors, Lawson said he is "encouraged" by the biopharma validation of CytomX's platform, while the company retains ownership of a major part of its pipeline, and believes ASCO and 2H data validates the CX-072 platform for safety and efficacy. Additionally, Lawson contends that 2H data for CX-2009 will validate the company's strategy of targeting "undruggable" antigens, unlocking two components of CytomX's valuation. Further, he believes three readouts in 2018 -- updated CX-027 data at ASCO, initial Phase 1/2 data from CX-2009 in the second half of the year, and follow-on Phase 1/2 data from CX-072 in the second half -- could be positive for the company.

TODAY'S FREE FLY STORIES

BMY

Bristol-Myers

$53.18

0.16 (0.30%)

07:00
10/22/19
10/22
07:00
10/22/19
07:00
Hot Stocks
Bristol-Myers: CheckMate -9LA Phase 3 trial met primary endpoint »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 18

    Nov

NVS

Novartis

$86.55

-0.305 (-0.35%)

07:00
10/22/19
10/22
07:00
10/22/19
07:00
Earnings
Novartis reports Q3 core EPS $1.41, consensus $1.33 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 28

    Oct

  • 06

    Nov

  • 07

    Dec

TRV

Travelers

$141.77

0.33 (0.23%)

07:00
10/22/19
10/22
07:00
10/22/19
07:00
Earnings
Travelers reports Q3 core income $1.43, consensus $2.35 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

PG

Procter & Gamble

$119.04

1.55 (1.32%)

06:59
10/22/19
10/22
06:59
10/22/19
06:59
Hot Stocks
Procter & Gamble reports Q1 operating cash flow $4.2B »

Operating cash flow was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

UTX

United Technologies

$138.24

1.39 (1.02%)

06:58
10/22/19
10/22
06:58
10/22/19
06:58
Earnings
United Technologies reports Q3 adj. EPS $2.21, consensus $2.03 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

PG

Procter & Gamble

$119.04

1.55 (1.32%)

06:58
10/22/19
10/22
06:58
10/22/19
06:58
Hot Stocks
Procter & Gamble CEO says 'we delivered strong top-line growth' in Q1 »

"We delivered strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

UA

Under Armour

$18.17

0.35 (1.96%)

, UAA

Under Armour

$20.09

0.39 (1.98%)

06:57
10/22/19
10/22
06:57
10/22/19
06:57
Hot Stocks
Under Armour appoints COO Patrik Frisk as CEO, effective Jan. 1 »

The board of Under Armour…

UA

Under Armour

$18.17

0.35 (1.96%)

UAA

Under Armour

$20.09

0.39 (1.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 04

    Nov

  • 04

    Nov

PG

Procter & Gamble

$119.04

1.55 (1.32%)

06:57
10/22/19
10/22
06:57
10/22/19
06:57
Earnings
Procter & Gamble raises FY20 outlook »

"The company raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

TRU

TransUnion

$82.55

1.055 (1.29%)

06:56
10/22/19
10/22
06:56
10/22/19
06:56
Earnings
TransUnion sees Q4 adjusted EPS 69c-71c, consensus 70c »

Sees Q4 adjusted revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 19

    Nov

VAR

Varian Medical

$116.41

1.67 (1.46%)

06:56
10/22/19
10/22
06:56
10/22/19
06:56
Recommendations
Varian Medical analyst commentary  »

Varian Medical offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 15

    Nov

HOG

Harley-Davidson

$37.14

0.555 (1.52%)

06:56
10/22/19
10/22
06:56
10/22/19
06:56
Hot Stocks
Harley-Davidson backs FY19 motorcycle shipments view of 212,000-217,000 »

For the full year 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

UA

Under Armour

$18.17

0.35 (1.96%)

, UAA

Under Armour

$20.09

0.39 (1.98%)

06:55
10/22/19
10/22
06:55
10/22/19
06:55
Hot Stocks
Breaking Hot Stocks news story on Under Armour, Under Armour »

Under Armour appoints COO…

UA

Under Armour

$18.17

0.35 (1.96%)

UAA

Under Armour

$20.09

0.39 (1.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 04

    Nov

  • 04

    Nov

PG

Procter & Gamble

$119.04

1.55 (1.32%)

06:55
10/22/19
10/22
06:55
10/22/19
06:55
Hot Stocks
Breaking Hot Stocks news story on Procter & Gamble »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

PG

Procter & Gamble

$119.04

1.55 (1.32%)

06:55
10/22/19
10/22
06:55
10/22/19
06:55
Earnings
Procter & Gamble reports Q1 core EPS $1.37, consensus $1.24 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

HOG

Harley-Davidson

$37.14

0.555 (1.52%)

06:54
10/22/19
10/22
06:54
10/22/19
06:54
Hot Stocks
Harley-Davidson reports Q3 retail motorcycle sales down 1.2% to 58,522 units »

U.S.Harley-Davidson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

TRU

TransUnion

$82.55

1.055 (1.29%)

06:54
10/22/19
10/22
06:54
10/22/19
06:54
Earnings
TransUnion sees FY19 adjusted EPS $2.74-$2.76, consensus $2.69 »

Sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 19

    Nov

BIIB

Biogen

$223.57

3.52 (1.60%)

06:54
10/22/19
10/22
06:54
10/22/19
06:54
Hot Stocks
Biogen reports Q3 MS revenues up 2% to $2.348B »

Multiple sclerosis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

HOG

Harley-Davidson

$37.14

0.555 (1.52%)

06:53
10/22/19
10/22
06:53
10/22/19
06:53
Earnings
Harley-Davidson reports Q3 adjusted EPS 70c, consensus 52c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

DGX

Quest Diagnostics

$102.21

-0.465 (-0.45%)

06:53
10/22/19
10/22
06:53
10/22/19
06:53
Earnings
Quest Diagnostics narrows FY19 adj. EPS view to $6.45-$6.50 from over $6.40 »

Consensus $6.50. Narrows…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 28

    Oct

  • 04

    Nov

  • 07

    Dec

BIIB

Biogen

$223.57

3.52 (1.60%)

06:52
10/22/19
10/22
06:52
10/22/19
06:52
Earnings
Biogen reports Q3 adjusted EPS $9.17, consensus $8.27 »

Reports Q3 revenue $3.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

TRU

TransUnion

$82.55

1.055 (1.29%)

06:51
10/22/19
10/22
06:51
10/22/19
06:51
Earnings
TransUnion reports Q3 adjusted EPS 76c, consensus 71c »

Reports Q3 revenue $689M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 19

    Nov

POL

PolyOne

$31.67

-0.065 (-0.20%)

06:50
10/22/19
10/22
06:50
10/22/19
06:50
Earnings
PolyOne reports Q3 adj. EPS 44c, consensus 43c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

DGX

Quest Diagnostics

$102.21

-0.465 (-0.45%)

06:50
10/22/19
10/22
06:50
10/22/19
06:50
Earnings
Quest Diagnostics reports Q3 adj. EPS $1.76, consensus $1.71 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 28

    Oct

  • 04

    Nov

  • 07

    Dec

HAS

Hasbro

$120.11

-1.78 (-1.46%)

06:49
10/22/19
10/22
06:49
10/22/19
06:49
Hot Stocks
Hasbro to suspend share repurchase program »

At quarter-end, $367.8M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

MTG

MGIC Investment

$13.74

0.22 (1.63%)

06:48
10/22/19
10/22
06:48
10/22/19
06:48
Earnings
MGIC Investment reports Q3 adj. EPS 48c, consensus 42c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.